RAE Health brings wearable technology and patented algorithms tied to a mobile app to allow users, providers,
and caregivers the ability to identify, detect, and track patterns of cravings, stress, and drug use. The RAE system facilitates the
engagement of patients suffering from substance use disorders in real-time while informing treatment providers—
ultimately helping to save lives and reduce the rate of relapse.

Realize

M-Health Technology provides recognition of stress and cravings supported by education and real-time
tools to de-escalate symptoms to the individual (Quantifiable Self).

Analyze

 Data produced by this technology aids in creating a seamless and comprehensive overview
of what is occurring in each patient throughout all stages of treatment. Substance use disorder professionals and treatment
providers can better tailor treatment options and support to the patients current needs.

Engage

Substance use disorder professionals and treatment providers are in need of solutions to reduce relapse, improve outcomes, and keep alumni and clients engaged in their treatment protocols. RAE's system facilitates patient engagement in real-time when the patient needs it most.

RAE Health Team
Chris.PNG
Chris Hassan, CEO

Chris Hassan serves as the Chief Executive Officer of RAE Health. Mr. Hassan is a leading healthcare CEO and has over 20 years’ experience in the field.  Chris started in the field training under Dr. David Smith, founder of the Haight Ashby Free Clinic, while working on development of depot naltrexone for the treatment of alcohol and opiate dependency. 

 

A founding member of Reckitt Benckiser Pharmaceuticals (now Indivior) he led the US commercial launch of Suboxone with sales of $200MM at launch.  Chris served as President and CEO of Colonial Management Group, one of the largest national providers of opiate dependence treatment growing the organization to 61 facilities serving over 23,000 patients in 21 states and over $100MM while transforming the organization.

 

Most recently Chris acquired, developed, and launched Symetria Health, a comprehensive treatment clinic group utilizing a data-driven tracking system across the entire treatment team.  Under Chris’ leadership and vision, Symetria developed an outcomes-based treatment program resulted in a successful ‘pay for performance’ model that delivered differentiated care for increased value capture. 

A passionate patient advocate, Chris has a focus on increasing patient access to treatment, leveraging therapy and pharmaceuticals in routinized care systems, and in driving measurable and repeatable outcomes for the benefit of patients, payers, and providers.

meg.jpeg
Megan Reinhardt, Co-Founder

Megan Reinhardt is the Co-Founder of RAE Health. She is also the CO-PI for a current fast track grant awarded by the NIH, named “RAE (Realize, Analyze, Engage”)- A Digital Biomarker Based Detection and Intervention System for Stress and Craving During Recovery from Substance Abuse Disorders.” She has held various executive positions, in publicly traded, start-up and private sectors, primary within molecular diagnostics for over a decade.  Her professional skill set with M&A, payor contracting, creating operational processes and efficiencies, regulatory, due-diligence and compliance has created a unique perspective to hone RAE’s vision.

 

As a problem solver who is driven to create efficient solutions and services that positively impact society, her passion and ultimate goal is to reduce suffering, stigma and relapse rates for individuals afflicted with substance use disorder.  From coastal Maine, she is the proud mom of two incredible teenagers. 

Fullsize_edited_edited.png
Nicole Gilbertson, Co-Founder

Ms. Gilbertson has eighteen years of experience building, growing, and founding innovative organizations. The past decade her career has focused in Clinical Laboratories, specifically addiction medicine. Prior to RAE, she served as the Western US Director of Sales for Alere Toxicology a global leading $600MM toxicology organization recently acquired by Abbott. She has extensive relationships with key industry leaders and corporate contacts in the addiction field. Her passion to drive change and positively impact the outcomes of individuals suffering from SUD has been a personal mission.  A native of Washington, she graduated cum laude from Washington State University with a B.A. in Business Administration and currently resides in California.

Dr. Stephanie Carreiro
Research Team
Stephanie Carreiro, MD

Dr. Stephanie Carreiro, MD is an emergency medicine physician and medical toxicologist. She is a 2009 graduate of New York Medical College and completed her Emergency Medicine Residency in 2013 at Brown University. She completed a medical toxicology fellowship at the University of Massachusetts Medical School
in 2015 and remained on faculty as an Assistant Professor of Emergency Medicine. Dr. Carreiro has a passion
for translational research, which she first discovered while evaluating novel antidotes for toxin-induced cardiac arrest in animal models. Over the last six years she has focused her clinical research in the substance use disorder space, with a particular focus on the current opioid epidemic. Her current research interests include
the utilization of of novel technologies and serum biomarkers to evaluate drug toxicity, substance abuse, and addiction. In a series of progressive investigations, she and her multidisciplinary team have demonstrated the ability of a state-of-the-art wearable biosensor to detect cocaine and opioid use, opioid withdrawal, stress,
and drug craving. She is the recipient of multiple industry and federally funded research grants, including a
K23 Mentored Career Development Award and a R44 Small Business Innovation and Research Award, both
from the National Institute on Drug Abuse. 

Dr. Carreiro has been collaborating with RAE since 2015;  her work on the RAE project builds logically on her prior accomplishments to focus on drug craving and stress in a population at high risk for relapse.  The data acquired from the ongoing RAE research will serve to optimize the digital biomarkers associated with drug craving and will also be applied in a much broader sense to enhance wearable sensor-triggered mobile interventions.  Ultimately this work aims to increase awareness, decrease craving, and promote successful recovery from drug addiction. 

premananda_indic.jpeg
Research Team
Premananda Indic, Ph.D.

Dr. Indic, currently serves as assistant professor in the Department of Electrical Engineering at UT Tyler. He completed his postdoctoral training in medicine from Harvard Medical School in 2004, obtained his Ph.D. from faculty of technology at the Cochin University of Science and Technology, India, in 2001, an M. Tech. degree in electrical engineering and B. Tech. degree in electrical & electronics engineering both from the University of Calicut, India. Prior to joining UT Tyler, he has been a faculty in the Department of Neurology at the University
of Massachusetts Medical School.

 

Dr. Indic is a Principal Investigator of Analytical Core of a National Institute of Health UO1 grant in which his team is developing big data analytics for risk stratification of preterm infants. He is a co-investigator on a Department of Veterans Affairs grant that focuses on developing a wearable sensor system for the detection
of suicidal ideation in military veterans. He has been an investigator on several federal grants and was a lead Principal Investigator of a National Science Foundation, Smart & Connected Health grant, where his team
was involved in developing a wearable biosensor system for the prediction of life-threatening events in preterm infants.

 

Dr. Indic is a Senior Member of the Institute of Electrical and Electronics Engineers (IEEE)

sarah-tsou-web_edited.jpg
Advisor
Sarah Tsou

Sarah Tsou is an Investment Manager and Legal Counsel for Omni Bridgeway. Prior to joining the company’s New York office, Sarah was a partner in the intellectual property practice group at Kirkland & Ellis LLP, focusing on patent litigation in a broad range of industries including medical devices, biotechnology, pharmaceuticals, and high tech. In addition to handling patent disputes, she also led trade secret and trademark litigation teams and counseled clients in corporate acquisitions, licensing matters, and other transactions. With over a dozen years
of experience representing clients in all aspects of complex litigation from inception to trial, Sarah has advised companies ranging from start-ups to Fortune 100 companies on strategy, risk, and IP portfolio and market analysis, and continues to offer valuable insights to companies and their counsel in her role at Bentham. Sarah earned her JD from New York University School of Law and her BA in Biology and Psychology from Washington University in St. Louis, graduating summa cum laude, with Highest Honors. 

Tim Cheney.png
Advisor
Tim Cheney

Tim is the managing partner of Choopersguide.com, co-founder and President of The Choopers Foundation,
a technology advisor to Orion Bio-Networks, a member of the Maine Substance Abuse Service Commission
and a consultant to Patrick Kennedy’s addiction and mental health initiatives. After founding and selling two human resource and technology companies to an international public company, he served as SVP and
Regional Executive SVP. As International Technology Division Chairman, he negotiated the Staffing industry’s first cooperation agreements with China in 2000. Tim was the City of Boston Drug Treatment Program
Research Director and the New Haven Community Correctional Center’s Program Director. As Boston’s SMSA representative and member of the Community Correspondents Group, he authored five NIDA epidemiological publications. Tim received a BA from Boston University (Summa Cum Laude with Distinction, Phi Beta Kappa). He attended Yale Divinity School and holds designations of Certified Personnel Consultant and Certified International Personnel Consultant.

Siobhan A. Morse.png
Advisor
Siobhan A. Morse, MHSA, CRC, CAI, MAC

Siobhan is the Divisional Director of Clinical Service-Research/Special Projects for the Behavioral Health Division of Universal Health Services (UHS). At UHS she focuses on developing facility programs addressing the opioid crisis and to share the findings from these programs with the industry at large. A regular presenter of her research efforts worldwide, she has published multiple articles in peer reviewed scientific journals and conducts education within the addiction services network.

 

Ms. Morse earned her certification as a Clinical Research Coordinator (CRC) from the Associates of Clinical Pharmacology and conducted over 100 clinical trials with pharmaceutical companies investigating new and promising treatments. She holds certifications as an ARISE Interventionist and as a Master Addiction Counselor.  September of 2020 Siobhan was awarded a Presidential Proclamation by the White House and the Office of National Drug Control Policy in recognition of her contribution to the field of substance use recovery.

 

Siobhan holds a Master’s degree in Health Services Administration from Florida International University. 

jim.png
Advisor
Jim Haggerty

Chief Executive Addiction Recovery and Mental Health Professional with 26 years of experience in the field starting in 1995.  Jim began his career as a Counselor in Training at Tully Hill Addiction Treatment in Upstate NY.  Over Jim’s 17 years in upstate NY he was the Admissions Director, supervised Utilization Review, IT, QA, Accounts Receivable, Billing, served as Chief Information Officer and Revenue Cycle Administrator and interacted with Marketing. After relocation to NJ, Jim formed his own Consulting Firm in 2012 Apogee System Consultants, working with numerous small to mid-sized Substance Abuse Facilities, start-ups to well established treatment centers, helping to enhance systems, create true Revenue Cycle Solutions, improve workflow, implement and integrate  Electronic Health Records to include enhanced real time reporting, generating profit centers while also creating dynamic cultures in order to turn around struggling facilities. 

 

Jim has imbedded himself and his team into Executive Level positions through his consulting firm as well as worked for a number of Substance Abuse facilities directly as CEO, CIO and CTO as well.  Jim believes in people, and continues to volunteer his time as an advisor, board member and interventionist always striving to make a difference.  Jim currently serves as Board Chair for the ECHO Foundation, a team member of the St James Church in Pennington NJ HOPE Ministry and as an advisor for The F.A.RM. Team in Lambertville NJ. 

James Bailey.png
Advisor
James Bailey, M.Ed., M.H.A.

James is a highly esteemed leader and visionary at the top of the healthcare field. Adept at complicated behavioral health program turnarounds, he quickly built a reputation for developing cultures that led to successful programs. From his multitude of turnarounds, James knows that employee engagement, combined with clinical excellence, results in the highest quality of patient care, leading to robust financial outcomes. Over the years of working with various equity firms, he has proven his ability to crack the code for success within this highly specialized industry, as the levers that lead to success in the behavioral healthcare field are frequently counter-intuitive to those in other industries.

 

With his experience as a CEO, COO, and Regional Vice President, James specializes in righting foundering programs, most notably The Camp Recovery Center and Sober Living by the Sea within the Acadia network, Cottonwood Treatment Center, Benchmark Behavioral Health Systems Hawaii, and Recovery Ways. Other areas of expertise include program start-up, program due diligence, and acquisition, increasing EBITDA by optimizing key performance indicators, and leading capital investment companies to success within the unique world of behavioral healthcare.

James holds a Master of Healthcare Administration from the University of Minnesota, a Master of Education from Northern Arizona University and a Bachelor of Psychology from Arizona State University.

 Sanjay Malkani.png
Advisor
Sanjay Malkani

For the decade ending Q1’18, Sanjay served as Global President of the Toxicology division of Alere, Inc (NYSE: ALR), the Global leader in diversified toxicology products, services and rapid point-of-care diagnostics. Sanjay was the original platform consolidator in the Toxicology market and grew the business from ~$50MM to ~$650MM, deploying ~$1.1B into over 30 merged assets to form a stand-alone division of 2,500+ employees across all major world regions, and delivered on a significant value creation model with a strong return on capital as measured by a leading Global strategy and Board advisory firm.

 

As a named executive officer and member of the company’s executive team, Sanjay supported Alere’s $5.3 billion sale in 2017 to Abbott Laboratories, Inc (NYSE: ABT). 

 

Sanjay has executive experience across diversified In-Vitro Diagnostics platforms - including Biologics, Point-of-Care Diagnostics, Laboratory Services and Health Information Solutions - and has developed the world-leading business in every healthcare category he has worked in. He held successive executive and commercial leadership positions within the Point-of-Care and Diabetes Care divisions of Roche Diagnostics, Inc. from 2001 to 2008, and within the Specialty Chemicals division of Dow Chemical, Inc.

 

Sanjay holds an MBA from the Kellogg School at Northwestern University (1998) and an undergraduate degree in Industrial Engineering from Purdue University (1991). 

scott.jpg
Advisor
Scott Taillie

Mr. Taillie currently a Vice President of Clinical Sales for Abbott Laboratories is a top-tier executive leader whose entrepreneurial vision has launched him from homegrown start-up to global Vice President. Across three Vice Presidencies and over 50 mergers and acquisitions, Scott has developed deep expertise in cultivating relationships across industries, negotiating mutually beneficial acquisitions, and generating outstanding operational synergy during the incorporation phase for each new company.

Kirk Cizerle_edited.jpg
Advisor
Kirk Cizerle

As the CEO and Founder of RecoveryTrek Kirk brings over 20 years of experience in Information Technology and Technical Management. Prior to forming RecoveryTrek, Kirk was the Chief Information Officer for FirstLab. He has extensive experience serving the federal, state, & local governments, as well as healthcare industries, and currently serves approximately 15,000 participants nationwide.

 

RecoveryTrek, provides state-of-the-art; customized software for organizations and individuals focused on behavioral health and reduction of substance abuse. Since 2011 RecoveryTrek has partnered with a wide variety of professional monitoring programs, treatment centers, non-profit organizations and individuals all with a desire to incorporate the most advanced evidenced-based tools including software, mobile, and laboratory solutions into their treatment protocols. Kirk has his bachelor’s degree in Chemistry from the University of
North Carolina and a MBA.